Re­lay Ther­a­peu­tics points to drug price ne­go­ti­a­tions for de­lay in po­ten­tial block­buster can­cer drug

While it may ul­ti­mate­ly be im­pos­si­ble to ver­i­fy why ex­act­ly a clin­i­cal-stage biotech would de­lay a po­ten­tial new drug ap­proval, Re­lay Ther­a­peu­tics said yes­ter­day that it will push back seek­ing ap­proval for its po­ten­tial FGFR2 se­lec­tive in­hibitor RLY-4008 (li­rafu­gra­tinib) in bile duct can­cer to wait for a larg­er in­di­ca­tion be­cause of in­com­ing gov­ern­ment drug price ne­go­ti­a­tions.

The de­ci­sion comes as the com­pa­ny al­so an­nounced yes­ter­day promis­ing new da­ta for li­rafu­gra­tinib in pa­tients with FGFR2-al­tered sol­id tu­mors, demon­strat­ing ac­tiv­i­ty across sev­er­al sub-groups, in­clud­ing pa­tients with FGFR2-fu­sion tu­mors and pa­tients with FGFR2-al­tered HR+/HER2- breast can­cer, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER